Scripps Florida's Translational Research Institute combines basic research with advanced technology platforms to develop potential lead compounds that can prevent, treat or cure disease. The Translational Research Institute works closely with the Scripps Florida academic departments to bring translational approaches to bear on complex biological problems.
The Translational Research Institute (TRI) includes the following components: Discovery Biology, Drug Metabolism and Pharmacokinetics (DMPK), TRI-Informatics, Lead Identification and HTS, and Medicinal Chemistry. These groups collaborate in the discovery and development of therapeutic agents for unmet medical needs for a variety of diseases.
Discovery Biology is involved in molecular targets thought to be involved in human diseases. Scientists use biochemical, molecular, and cellular techniques to understand mechanism of action and evaluate how well compounds perform as a potential therapy and how effectively and safely they interact with intended targets.
Drug Metabolism and Pharmacokinetics (DMPK) supports the development of new drugs through performance of physical measurements and formulation, in vitro and in vivo metabolism, and pharmacokinetics. These studies tell scientists how stable a drug candidate is, how rapidly a potential drug is cleared from the body, how a potential drug interacts with enzymes in the intestines and liver, and how well a drug candidate crosses the blood-brain barrier.
Lead Identification and HTS supports assay development and high throughput screening of large compound collections against biological targets implicated in various diseases. Promising candidates from these screens are then examined further in collaboration with scientists in the DMPK, Discovery Biology, Informatics, and Medicinal Chemistry groups. Narrowing the research field to those few compounds that show promise for development is one of the most crucial jobs in early hit to lead expansion.
Medicinal Chemistry designs and modifies biologically active chemical entities that target specific enzymes or receptors with the goal of optimizing their therapeutic properties and value. Working in concert with their colleagues in Lead ID, Informatics, Discovery Biology, and DMPK, investigators in Medicinal Chemistry are focused on a variety of disease areas, including cancer, diabetes, autoimmune disorders, and Parkinson's disease.
TRI-Informatics manages and mines the wealth of scientific data-both existing data generated from projects like the Human Genome Project and all the new data generated by Scripps Research scientists. Informatics investigators work with other groups to design software interfaces and platforms that can assist in experiments such as the development of special applications to analyze data streams from high throughput technology and analytical tools for large-scale proteomic studies.